Milestone Pharmaceuticals Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $559,000 for the three months ended June 30, 2026, and $797,000 for the six months ended June 30, 2026. This marks a significant increase compared to the same periods in 2025, during which the company reported no revenue. The revenue generated is attributed to the sales of its product, CARDAMYST™ (etripamil) nasal spray, which was launched in February 2026 following FDA approval in December 2025. Despite the revenue growth, the company recorded a net loss of $28.6 million for the second quarter and $54.7 million for the first half of 2026, compared to losses of $13.0 million and $33.7 million in the respective periods of 2025.

Operating expenses for Milestone Pharmaceuticals increased significantly, with total operating expenses reaching $26.2 million for the second quarter of 2026, up from $12.5 million in the same quarter of 2025. The increase was primarily driven by a 156% rise in selling, general, and administrative expenses, which totaled $22.6 million, reflecting the costs associated with the commercialization of CARDAMYST. Research and development expenses decreased slightly to $3.5 million for the second quarter, down from $3.7 million in the prior year, indicating a shift in focus towards commercialization efforts.

The company’s balance sheet as of June 30, 2026, showed total assets of $181.6 million, a substantial increase from $113.6 million at the end of 2025. This growth was largely due to an increase in cash and cash equivalents, which rose to $169.7 million from $73.0 million, bolstered by proceeds from the Royalty Purchase Agreement and the exercise of warrants. Total liabilities also increased significantly to $163.4 million, primarily due to the royalty financing obligation and convertible notes.

Milestone Pharmaceuticals is actively pursuing the commercialization of CARDAMYST and is also developing etripamil for additional indications, including atrial fibrillation with rapid ventricular rate (AFib-RVR). The company has initiated a Phase 3 clinical trial for AFib-RVR and expects to enroll the first patient in the second half of 2026. The company anticipates continued operating losses as it invests in the commercialization of CARDAMYST and the development of etripamil for other indications. Management believes that its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.

Looking ahead, Milestone Pharmaceuticals aims to expand its market presence and capitalize on the growing demand for innovative cardiovascular treatments. The company is focused on increasing its sales and marketing capabilities while exploring potential collaborations for further product development and commercialization. The management remains optimistic about the future growth prospects of CARDAMYST and the potential for etripamil in treating additional cardiovascular conditions.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals develops innovative cardiovascular medicines, focusing on rapid-onset nasal spray treatments for arrhythmias like PSVT and AFib-RVR. Its flagship product, CARDAMYST (etripamil), aims to provide self-administered, fast-acting therapy for episodic heart rhythm disturbances. The company targets the U.S. and global markets, leveraging proprietary formulations, clinical data, and strategic partnerships to address unmet needs in acute cardiovascular care.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov